JP2008536865A - 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ - Google Patents
抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ Download PDFInfo
- Publication number
- JP2008536865A JP2008536865A JP2008506765A JP2008506765A JP2008536865A JP 2008536865 A JP2008536865 A JP 2008536865A JP 2008506765 A JP2008506765 A JP 2008506765A JP 2008506765 A JP2008506765 A JP 2008506765A JP 2008536865 A JP2008536865 A JP 2008536865A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- egfr
- skin
- analog
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 title claims abstract description 82
- 206010037844 rash Diseases 0.000 title claims abstract description 65
- 201000005884 exanthem Diseases 0.000 title claims abstract description 64
- 229930003448 Vitamin K Natural products 0.000 title claims abstract description 63
- 235000019168 vitamin K Nutrition 0.000 title claims abstract description 63
- 239000011712 vitamin K Substances 0.000 title claims abstract description 63
- 229940046010 vitamin k Drugs 0.000 title claims abstract description 63
- 208000010201 Exanthema Diseases 0.000 title claims abstract description 62
- 150000003721 vitamin K derivatives Chemical class 0.000 title claims abstract description 62
- 238000011282 treatment Methods 0.000 title claims description 40
- 238000011123 anti-EGFR therapy Methods 0.000 title claims description 21
- 230000002265 prevention Effects 0.000 title claims description 8
- 238000000034 method Methods 0.000 claims abstract description 78
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 34
- 229940122907 Phosphatase inhibitor Drugs 0.000 claims abstract description 33
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 26
- 102000009465 Growth Factor Receptors Human genes 0.000 claims abstract description 19
- 108010009202 Growth Factor Receptors Proteins 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 18
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 145
- 102000001301 EGF receptor Human genes 0.000 claims description 111
- 108060006698 EGF receptor Proteins 0.000 claims description 111
- 235000012711 vitamin K3 Nutrition 0.000 claims description 63
- 239000011652 vitamin K3 Substances 0.000 claims description 63
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 24
- 208000025865 Ulcer Diseases 0.000 claims description 24
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 24
- 231100000397 ulcer Toxicity 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 229960001433 erlotinib Drugs 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 20
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims description 19
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 claims description 19
- 235000019175 phylloquinone Nutrition 0.000 claims description 19
- 239000011772 phylloquinone Substances 0.000 claims description 19
- 229960001898 phytomenadione Drugs 0.000 claims description 19
- 229940121647 egfr inhibitor Drugs 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 14
- 238000013268 sustained release Methods 0.000 claims description 11
- 239000012730 sustained-release form Substances 0.000 claims description 11
- 230000030609 dephosphorylation Effects 0.000 claims description 10
- 238000006209 dephosphorylation reaction Methods 0.000 claims description 10
- 238000011200 topical administration Methods 0.000 claims description 10
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 9
- 229960005395 cetuximab Drugs 0.000 claims description 9
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 9
- 231100000046 skin rash Toxicity 0.000 claims description 9
- 229960002584 gefitinib Drugs 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 5
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
- 108010048999 Transcription Factor 3 Proteins 0.000 claims description 4
- 102100038313 Transcription factor E2-alpha Human genes 0.000 claims description 4
- 208000003265 stomatitis Diseases 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 3
- 230000011664 signaling Effects 0.000 claims description 3
- 208000014834 chemotherapy-induced oral mucositis Diseases 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 41
- 230000000694 effects Effects 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000006071 cream Substances 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 11
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 8
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 7
- 101800003838 Epidermal growth factor Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 235000019143 vitamin K2 Nutrition 0.000 description 7
- 239000011728 vitamin K2 Substances 0.000 description 7
- 229940041603 vitamin k 3 Drugs 0.000 description 7
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- -1 Vitamin K compounds Chemical class 0.000 description 3
- 206010047741 Vulval cancer Diseases 0.000 description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 3
- 229960001456 adenosine triphosphate Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 201000010536 head and neck cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 201000005102 vulva cancer Diseases 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- RYWSYCQQUDFMAU-UHFFFAOYSA-N Acetomenaphthone Chemical compound C1=CC=C2C(OC(=O)C)=CC(C)=C(OC(C)=O)C2=C1 RYWSYCQQUDFMAU-UHFFFAOYSA-N 0.000 description 2
- 0 CC(C(c1cc(I)c(*)cc11)=O)=C(*)C1=O Chemical compound CC(C(c1cc(I)c(*)cc11)=O)=C(*)C1=O 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940095399 enema Drugs 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940084651 iressa Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940120982 tarceva Drugs 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- BCKLPBBBFNWJHH-UHFFFAOYSA-N 2-methylnaphthalene-1,4-diamine Chemical compound C1=CC=CC2=C(N)C(C)=CC(N)=C21 BCKLPBBBFNWJHH-UHFFFAOYSA-N 0.000 description 1
- UGQFCTZXVAPVCS-UHFFFAOYSA-N 4-amino-2-methyl-1-naphthol Chemical compound C1=CC=CC2=C(O)C(C)=CC(N)=C21 UGQFCTZXVAPVCS-UHFFFAOYSA-N 0.000 description 1
- YJRCNAAPGQBVFS-UHFFFAOYSA-N 4-amino-3-methylnaphthalen-1-ol Chemical compound C1=CC=CC2=C(N)C(C)=CC(O)=C21 YJRCNAAPGQBVFS-UHFFFAOYSA-N 0.000 description 1
- OZIWSTQWWVNPDA-UHFFFAOYSA-N 4-amino-3-methylnaphthalen-1-ol;hydrochloride Chemical compound Cl.C1=CC=CC2=C(N)C(C)=CC(O)=C21 OZIWSTQWWVNPDA-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 208000031050 Skin vascular disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- UKHVLWKBNNSRRR-ODZAUARKSA-M dowicil 200 Chemical compound [Cl-].C1N(C2)CN3CN2C[N+]1(C\C=C/Cl)C3 UKHVLWKBNNSRRR-ODZAUARKSA-M 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940071149 erlotinib 100 mg Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100001106 life-threatening toxicity Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960004051 menadione sodium bisulfite Drugs 0.000 description 1
- XDPFHGWVCTXHDX-UHFFFAOYSA-M menadione sodium sulfonate Chemical compound [Na+].C1=CC=C2C(=O)C(C)(S([O-])(=O)=O)CC(=O)C2=C1 XDPFHGWVCTXHDX-UHFFFAOYSA-M 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 150000003718 vitamin K5 derivatives Chemical class 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67156305P | 2005-04-15 | 2005-04-15 | |
| PCT/US2006/014158 WO2006113479A2 (en) | 2005-04-15 | 2006-04-12 | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012196249A Division JP5620443B2 (ja) | 2005-04-15 | 2012-09-06 | 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008536865A true JP2008536865A (ja) | 2008-09-11 |
| JP2008536865A5 JP2008536865A5 (enExample) | 2009-05-28 |
Family
ID=37115750
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008506765A Withdrawn JP2008536865A (ja) | 2005-04-15 | 2006-04-12 | 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ |
| JP2012196249A Expired - Fee Related JP5620443B2 (ja) | 2005-04-15 | 2012-09-06 | 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012196249A Expired - Fee Related JP5620443B2 (ja) | 2005-04-15 | 2012-09-06 | 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7745494B2 (enExample) |
| EP (3) | EP2494965A3 (enExample) |
| JP (2) | JP2008536865A (enExample) |
| KR (1) | KR101332869B1 (enExample) |
| AT (1) | ATE492275T1 (enExample) |
| AU (1) | AU2006236633B2 (enExample) |
| CA (2) | CA2851079A1 (enExample) |
| CY (1) | CY1111786T1 (enExample) |
| DE (1) | DE602006019074D1 (enExample) |
| DK (1) | DK1871353T3 (enExample) |
| ES (1) | ES2358528T3 (enExample) |
| PT (1) | PT1871353E (enExample) |
| WO (1) | WO2006113479A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012236857A (ja) * | 2005-04-15 | 2012-12-06 | Albert Einstein College Of Medicine Of Yeshiva Univ | 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ |
| JP2023132190A (ja) * | 2022-03-10 | 2023-09-22 | 学校法人福岡大学 | ケモカインｃｃｌ５発現抑制剤 |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| US9428582B2 (en) * | 2006-07-03 | 2016-08-30 | Genmab A/S | Method of treating rash in patients undergoing anti-EGFR therapy |
| US8815953B2 (en) * | 2008-03-13 | 2014-08-26 | Spectrum Pharmaceuticals, Inc. | Formulations of vitamin K analogs for topical use |
| US20100010100A1 (en) * | 2008-07-09 | 2010-01-14 | Hinman Andrew W | Dermatological compositions with anti-aging and skin even-toning properties |
| WO2010014361A1 (en) * | 2008-07-30 | 2010-02-04 | Edison Pharmaceuticals, Inc. | Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties |
| WO2010048330A1 (en) | 2008-10-21 | 2010-04-29 | Threshold Pharmaceuticals, Inc. | Treatment of cancer using hypoxia activated prodrugs |
| EP2445533B1 (en) * | 2009-06-26 | 2017-02-08 | Sunny Pharmtech Inc., | Method for treating or ameliorating mucocutaneous or ocular toxicities |
| ITPD20100090A1 (it) * | 2010-03-22 | 2011-09-23 | Sanitas Farmaceutici S R L | Formulazione topica per il trattamento di eruzioni cutanee, in particolare conseguenti a trattamenti con farmaci anti egfr |
| JP5062922B2 (ja) | 2011-02-14 | 2012-10-31 | 株式会社Ｊ−オイルミルズ | 皮膚コラーゲン産生促進剤 |
| EP2712613B1 (en) * | 2012-09-28 | 2017-02-08 | Pharmadab d.o.o. | Vitamin K1 and uses thereof |
| US9421297B2 (en) | 2014-04-02 | 2016-08-23 | Adhezion Biomedical, Llc | Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides |
| EP3250180B1 (en) | 2015-01-27 | 2026-03-11 | Lesaffre et Compagnie | Pharmaceutical composition comprising vitamin k2 for use in the treatment or prevention of melanoma |
| TW201927292A (zh) | 2017-12-13 | 2019-07-16 | 大陸商上海小午醫藥科技有限公司 | 一種用於預防或治療與ｅｇｆｒ被抑制相關疾病的方法 |
| AU2019254237B2 (en) | 2018-04-16 | 2025-01-30 | Onquality Pharmaceuticals China Ltd. | Method for preventing or treating side effects of cancer therapy |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997039746A1 (en) * | 1996-04-22 | 1997-10-30 | Advanced Polymer Systems, Inc. | Method of and composition for treating disorders of the skin using vitamin k |
| JP2002517436A (ja) * | 1998-06-11 | 2002-06-18 | ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュージャージー | アデノシン二リン酸リボシルトランスフェラーゼの阻害を介する創傷処置 |
| WO2003101415A1 (en) * | 2002-06-01 | 2003-12-11 | The Boots Company Plc | Compositions comprisins vitamin k |
| JP2004500392A (ja) * | 2000-03-17 | 2004-01-08 | ビーエーエスエフ アクチェンゲゼルシャフト | 水溶性ビタミンの油性懸濁液の製造方法 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA84119A (en) | 1903-11-06 | 1903-12-01 | Edward M. Haymaker | Cover and strainer for milk pails |
| CA91784A (en) | 1904-10-05 | 1905-02-28 | William Stevenson | Dining and billiard table |
| US3155031A (en) | 1962-03-16 | 1964-11-03 | Babco Products Inc | Printing and digital coding machine |
| US4294852A (en) | 1973-11-01 | 1981-10-13 | Johnson & Johnson | Skin treating compositions |
| DE3060165D1 (en) | 1979-03-08 | 1982-03-11 | Hoffmann La Roche | Process for the stereospecific preparation of compounds of the vitamin k1- and k2-series, as well as new starting materials for the process |
| JPS6025918A (ja) | 1983-07-25 | 1985-02-08 | Ajinomoto Co Inc | 脂溶性薬物含有水性液 |
| DE3406497A1 (de) | 1984-02-23 | 1985-09-05 | Mueller Bernhard Willi Werner | Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung |
| DE3514724A1 (de) | 1985-04-24 | 1986-10-30 | Albin F. Dr. 4200 Oberhausen Jereb | Salbe zur verbeugung und behandlung von augen- und hauterkrankungen |
| JPS62294636A (ja) | 1986-05-21 | 1987-12-22 | Eisai Co Ltd | ２−メチル−１，４−ナフトキノンの製造法 |
| US5180747A (en) | 1989-02-28 | 1993-01-19 | Nisshin Flour Milling Co., Ltd. | Stabilized fat-soluble vitamin compositions |
| ZA902066B (en) | 1989-04-14 | 1990-12-28 | Minnesota Mining & Mfg | Solid gel external drug delivery system |
| US4966779A (en) | 1989-12-21 | 1990-10-30 | Basf Corporation | Stable, water miscible emulsion comprising a fat-soluble vitamin |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5155031A (en) | 1990-06-07 | 1992-10-13 | Posner Barry I | Use of pervanadate as an inhibitor of phosphotyrosine phosphatase |
| FR2672288B1 (fr) | 1991-02-06 | 1993-04-23 | Oreal | Nouveaux amides dipeptidiques derivant de la glycyl-serine, utilisables, notamment dans des compositions cosmetiques, pharmaceutiques ou alimentaires. |
| DE4141351A1 (de) | 1991-12-14 | 1993-06-17 | Basf Ag | Stabile pulverfoermige vitamin- und/oder carotinoid-praeparate und verfahren zu deren herstellung |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US5785976A (en) | 1993-03-05 | 1998-07-28 | Pharmacia & Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| US5885486A (en) | 1993-03-05 | 1999-03-23 | Pharmaciaand Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
| US5643765A (en) | 1993-04-06 | 1997-07-01 | University Of Rochester | Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction |
| CA2117412A1 (en) | 1993-07-26 | 1995-01-27 | Eisai Co., Ltd. | Preparation process of naphthoquinone derivative and intermediate for the preparation thereof |
| US5510391A (en) | 1993-10-22 | 1996-04-23 | Mayapple Holdings, Llc | Method of treating blood vessel disorders of the skin using vitamin K |
| FR2719219B1 (fr) | 1994-05-02 | 1996-06-21 | Rocher Yves Biolog Vegetale | Composition cosmétique ou pharmaceutique à usage topique comprenant des vésicules lipidiques. |
| US5637741A (en) | 1994-09-27 | 1997-06-10 | Kuraray Co., Ltd. | Process for producing 2-methyl-1,4-naphthoquinone |
| JPH09143042A (ja) * | 1995-11-24 | 1997-06-03 | Lion Corp | 口腔用組成物 |
| KR0178456B1 (ko) | 1996-04-25 | 1999-05-15 | 김흥기 | 2-메틸-1,4-나프토퀴논(비타민 k3)의 제조방법 |
| SE9601665D0 (sv) | 1996-04-30 | 1996-04-30 | Bioglan Ab | Biologically active composition |
| US6110891A (en) | 1996-06-21 | 2000-08-29 | Alizyme Therapeutics Ltd. | Lectin compositions and uses thereof |
| DE19642359A1 (de) | 1996-10-14 | 1998-04-16 | Basf Ag | Stabile Emulsionen und Trockenpulver von Mischungen fettlöslicher Vitamine, deren Herstellung und Verwendung |
| US5916749A (en) | 1996-12-13 | 1999-06-29 | Incyte Pharmaceuticals, Inc. | Human phosphatase inhibitor protein |
| US6426078B1 (en) | 1997-03-17 | 2002-07-30 | Roche Vitamins Inc. | Oil in water microemulsion |
| US6599513B2 (en) | 1997-05-27 | 2003-07-29 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| US6372234B1 (en) | 1997-05-27 | 2002-04-16 | Sembiosys Genetics Inc. | Products for topical applications comprising oil bodies |
| AU1289899A (en) | 1997-10-31 | 1999-05-24 | Arch Development Corporation | Methods and compositions for regulation of 5-alpha reductase activity |
| US6696484B2 (en) | 1997-10-31 | 2004-02-24 | University Of Chicago Office Of Technology And Intellectual Property | Method and compositions for regulation of 5-alpha reductase activity |
| US6013665A (en) | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| US6207176B1 (en) | 1998-09-14 | 2001-03-27 | National Starch And Chemical Investment Holding Corporation | Starch based adhesives for skin cleaning tape |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| US6187822B1 (en) * | 1999-06-11 | 2001-02-13 | University Of Medicine & Dentistry Of Nj | Wound treatment through inhibition of adenosine diphosphate ribosyl transferase |
| US6524594B1 (en) | 1999-06-23 | 2003-02-25 | Johnson & Johnson Consumer Companies, Inc. | Foaming oil gel compositions |
| US7927612B2 (en) | 2000-01-19 | 2011-04-19 | Baofa Yu | Combinations and methods for treating neoplasms |
| DE10003786A1 (de) | 2000-01-28 | 2001-08-02 | Merck Patent Gmbh | Galenische Formulierung |
| DE60135732D1 (de) | 2000-02-28 | 2008-10-23 | Univ British Columbia | Topoisomerasehemmern zur behandlung von chirurgischen verklebungen |
| EP1276496B1 (en) | 2000-03-20 | 2005-06-15 | Pfizer Products Inc. | Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor |
| US20040047852A1 (en) | 2001-03-02 | 2004-03-11 | Kennedy Thomas Preston | Method of treating cancer |
| US20020040011A1 (en) | 2000-06-01 | 2002-04-04 | Brown Dennis M. | Naphthoquinone compositions and uses thereof |
| PL342071A1 (en) | 2000-08-18 | 2001-02-12 | Szolomicka Orfinger Irena | Cosmetic cream |
| GB0022079D0 (en) | 2000-09-08 | 2000-10-25 | Inst Of Molecul & Cell Biology | Novel protein tyrosine phosphatase inhibitor |
| US6660306B2 (en) | 2000-10-12 | 2003-12-09 | Mickey L. Peshoff | Wound healing compound |
| US7094431B2 (en) * | 2000-10-12 | 2006-08-22 | Mickey L. Peshoff | Method of healing skin wounds in mammals and a composition therefor |
| US6774100B2 (en) | 2000-12-06 | 2004-08-10 | Imaginative Research Associates, Inc. | Anhydrous creams, lotions and gels |
| US7604812B2 (en) | 2000-12-15 | 2009-10-20 | Patrick Franke | Hypoallergenic and non-irritant skin care formulations |
| ES2218055T3 (es) | 2000-12-15 | 2004-11-16 | Patrick Dr. Franke | Formulaciones hipoalergenicas y no irritantes para el cuidado de la piel. |
| US6780439B2 (en) * | 2001-03-06 | 2004-08-24 | J. Ronald Wilk | Wound treatment solution and method for using same |
| US6579994B2 (en) | 2001-03-29 | 2003-06-17 | Council Of Scientific And Industrial Research | Process for preparation of 2-Methyl-1,4-naphthoquinone |
| AU2002361550A1 (en) * | 2001-07-20 | 2003-04-22 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
| US6812220B2 (en) | 2001-08-29 | 2004-11-02 | University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
| US20070238697A1 (en) | 2001-08-29 | 2007-10-11 | University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
| US8156471B2 (en) | 2001-11-09 | 2012-04-10 | Oracle International Corporation | Multi-language execution method |
| US7405188B2 (en) | 2001-12-12 | 2008-07-29 | Wsp Chemicals & Technology, Llc | Polymeric gel system and compositions for treating keratin substrates containing same |
| JP4502641B2 (ja) | 2002-01-24 | 2010-07-14 | ティルタン ファーマ リミテッド | 抗癌組み合わせおよびその使用方法 |
| JP2003226639A (ja) | 2002-01-31 | 2003-08-12 | Hisamitsu Pharmaceut Co Inc | 神経成長因子活性増強剤としてのビタミンｋ類を含む医薬組成物およびその使用 |
| US20030170187A1 (en) | 2002-03-01 | 2003-09-11 | Alfred Marchal | Skin treatments containing nano-sized vitamin K |
| GB0220182D0 (en) | 2002-08-30 | 2002-10-09 | Cardiovascular Res Inst Maastr | Organic compounds |
| US7326690B2 (en) | 2002-10-30 | 2008-02-05 | Bach Pharma, Inc. | Modulation of cell fates and activities by phthalazinediones |
| WO2004098569A1 (en) | 2003-04-18 | 2004-11-18 | Northeastern University | Micelle delivery system loaded with a pharmaceutical agent |
| JP2005020651A (ja) | 2003-06-30 | 2005-01-20 | Hitachi Ltd | タイムスタンプ情報検証方法 |
| US7320797B2 (en) | 2003-08-29 | 2008-01-22 | Bioderm Research | Antiaging cosmetic delivery systems |
| BRPI0414907A (pt) | 2003-09-30 | 2006-11-07 | Acusphere Inc | formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas |
| US20050092969A1 (en) | 2003-10-08 | 2005-05-05 | Kaneka Corporation | Method of stabilizing compound having quinone skeleton and stabilized composition |
| JP2005206521A (ja) | 2004-01-22 | 2005-08-04 | Nippon Menaade Keshohin Kk | 抗菌剤 |
| KR20060002239A (ko) | 2004-07-01 | 2006-01-09 | 삼성전자주식회사 | 레이저 출력 제어장치 |
| US7691418B2 (en) | 2004-09-17 | 2010-04-06 | Oystershell Nv | Composition for inhibiting or preventing the formation of a biofilm |
| CN101068561A (zh) | 2004-10-06 | 2007-11-07 | 蒂尔坦制药有限公司 | 用于加强抗血管生成疗法的方法和组合物 |
| WO2006107827A1 (en) | 2005-04-05 | 2006-10-12 | Creighton University | Skin bonding process |
| EP2494965A3 (en) | 2005-04-15 | 2013-01-02 | The Albert Einstein College Of Medicine Of Yeshiva University | Vitamin K for Prevention and Treatment of Skin Rash Secondary to Anti-EGFR Therapy |
| US20060275504A1 (en) | 2005-06-07 | 2006-12-07 | Tty Biopharm Company Limited | Methods and compositions for augmenting cancer chemotherapeutic agents |
| US20070025950A1 (en) | 2005-07-28 | 2007-02-01 | Elson Melvin L | Composition and method for treating cellulite |
| US7252816B1 (en) | 2006-03-29 | 2007-08-07 | Dow Pharmaceutical Sciences | Topical acne vulgairs medication with a sunscreen |
| CA2689717C (en) | 2006-06-16 | 2016-10-18 | Summa Health System | Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone |
| JP2009542623A (ja) | 2006-07-07 | 2009-12-03 | ティルタン ファーマ リミテッド | Ｈ２遮断薬、少なくとも１つの抗炎症薬剤および細胞毒性薬剤を含む抗がん治療 |
-
2006
- 2006-04-12 EP EP11189225A patent/EP2494965A3/en not_active Withdrawn
- 2006-04-12 CA CA2851079A patent/CA2851079A1/en not_active Abandoned
- 2006-04-12 AT AT06750246T patent/ATE492275T1/de active
- 2006-04-12 WO PCT/US2006/014158 patent/WO2006113479A2/en not_active Ceased
- 2006-04-12 PT PT06750246T patent/PT1871353E/pt unknown
- 2006-04-12 KR KR1020077026480A patent/KR101332869B1/ko not_active Expired - Fee Related
- 2006-04-12 CA CA2603785A patent/CA2603785C/en not_active Expired - Fee Related
- 2006-04-12 DE DE602006019074T patent/DE602006019074D1/de active Active
- 2006-04-12 JP JP2008506765A patent/JP2008536865A/ja not_active Withdrawn
- 2006-04-12 AU AU2006236633A patent/AU2006236633B2/en not_active Ceased
- 2006-04-12 DK DK06750246.8T patent/DK1871353T3/da active
- 2006-04-12 ES ES06750246T patent/ES2358528T3/es active Active
- 2006-04-12 EP EP06750246A patent/EP1871353B1/en active Active
- 2006-04-12 US US11/886,803 patent/US7745494B2/en not_active Expired - Fee Related
- 2006-04-12 EP EP10195772.8A patent/EP2305224B1/en active Active
-
2009
- 2009-05-14 US US12/465,980 patent/US20090239952A1/en not_active Abandoned
-
2010
- 2010-05-26 US US12/788,015 patent/US8283382B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 CY CY20111100295T patent/CY1111786T1/el unknown
-
2012
- 2012-09-06 JP JP2012196249A patent/JP5620443B2/ja not_active Expired - Fee Related
- 2012-09-20 US US13/623,625 patent/US20130225690A1/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997039746A1 (en) * | 1996-04-22 | 1997-10-30 | Advanced Polymer Systems, Inc. | Method of and composition for treating disorders of the skin using vitamin k |
| JP2002517436A (ja) * | 1998-06-11 | 2002-06-18 | ユニバーシティ オブ メディスン アンド デンティストリー オブ ニュージャージー | アデノシン二リン酸リボシルトランスフェラーゼの阻害を介する創傷処置 |
| JP2004500392A (ja) * | 2000-03-17 | 2004-01-08 | ビーエーエスエフ アクチェンゲゼルシャフト | 水溶性ビタミンの油性懸濁液の製造方法 |
| WO2003101415A1 (en) * | 2002-06-01 | 2003-12-11 | The Boots Company Plc | Compositions comprisins vitamin k |
Non-Patent Citations (4)
| Title |
|---|
| JPN6012010566; ＢＵＳＡＭ，Ｋ．Ｊ． ｅｔ ａｌ， Ｃｕｔａｎｅｏｕｓ ｓｉｄｅ-ｅｆｆｅｃｔｓ ｉｎ ｃａｎｃｅｒ ｐａｔｉｅｎｔｓ ｔｒｅａｔｅｄ ｗｉｔｈ ｔｈｅ ａｎｔｉｅｐｉｄｅｒｍａｌ ｇｒｏｗｔｈ ｆａ * |
| JPN6012010568; 佐藤八千代他， 臨床皮膚科， ２００４， ｖｏｌ．５８， ｎｏ．５， ｐ．２８-３２ * |
| JPN6012010571; ＯＳＡＤＡ，Ｓ． ｅｔ ａｌ， Ｎｅｗ ａｐｐｒｏａｃｈ ｔｏ ｃａｎｃｅｒ ｔｈｅｒａｐｙ： ｔｈｅ ａｐｐｌｉｃａｔｉｏｎ ｏｆ ｓｉｇｎａｌ ｔｒａｎｓｄｕｃｔｉｏｎ ｔｏ ａｎｔｉ-ｃａｎｃｅ * |
| JPN6012010573; 足立尊仁他， 日本外科学会雑誌， ｖｏｌ．１０３， 臨時増刊号， ｐ．６５４ * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012236857A (ja) * | 2005-04-15 | 2012-12-06 | Albert Einstein College Of Medicine Of Yeshiva Univ | 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ |
| JP2023132190A (ja) * | 2022-03-10 | 2023-09-22 | 学校法人福岡大学 | ケモカインｃｃｌ５発現抑制剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP5620443B2 (ja) | 2014-11-05 |
| EP1871353A2 (en) | 2008-01-02 |
| US20090209652A1 (en) | 2009-08-20 |
| US20130225690A1 (en) | 2013-08-29 |
| US20100324148A1 (en) | 2010-12-23 |
| JP2012236857A (ja) | 2012-12-06 |
| CA2603785C (en) | 2014-07-22 |
| KR20070121843A (ko) | 2007-12-27 |
| HK1111920A1 (en) | 2008-11-07 |
| EP2305224A3 (en) | 2011-12-14 |
| WO2006113479A3 (en) | 2007-05-10 |
| EP2494965A3 (en) | 2013-01-02 |
| US7745494B2 (en) | 2010-06-29 |
| CA2851079A1 (en) | 2006-10-26 |
| EP1871353B1 (en) | 2010-12-22 |
| ES2358528T3 (es) | 2011-05-11 |
| CA2603785A1 (en) | 2006-10-26 |
| DK1871353T3 (da) | 2011-04-04 |
| WO2006113479A2 (en) | 2006-10-26 |
| KR101332869B1 (ko) | 2013-11-25 |
| DE602006019074D1 (de) | 2011-02-03 |
| EP2305224B1 (en) | 2015-03-11 |
| EP1871353A4 (en) | 2009-06-24 |
| CY1111786T1 (el) | 2015-10-07 |
| EP2494965A2 (en) | 2012-09-05 |
| PT1871353E (pt) | 2011-03-29 |
| US8283382B2 (en) | 2012-10-09 |
| US20090239952A1 (en) | 2009-09-24 |
| ATE492275T1 (de) | 2011-01-15 |
| AU2006236633A1 (en) | 2006-10-26 |
| EP2305224A2 (en) | 2011-04-06 |
| AU2006236633B2 (en) | 2012-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5620443B2 (ja) | 抗ｅｇｆｒ療法に二次的な皮疹の予防および処置のためのビタミンｋ | |
| WO2007092414A2 (en) | Use of phosphatases to treat tumors overexpressing n-cor | |
| US20090018142A9 (en) | Use of phosphatases to treat tumors overexpressing N-CoR | |
| WO2012099968A1 (en) | Compositions and methods for treating skin cancer associated diseases | |
| KR20100136997A (ko) | 암세포에서 아폽토시스를 유도하는 방법 및 용도 | |
| EP3730144A1 (en) | Agent for treatment of nervous system disease | |
| CN111818910A (zh) | 含有赛度替尼的局部用皮肤药物组合物及其应用 | |
| WO2023202989A1 (en) | Treatment of frontal fibrosing alopecia | |
| Danelli et al. | Leishmanicidal effect of LLD-3 (1), a nor-triterpene isolated from Lophanthera lactescens | |
| Ross | Cannabis and Cancer | |
| TW201444561A (zh) | 可治療癌症之藥學組合物 | |
| EP3846789B1 (en) | Composition comprising histone deacetylase inhibitor and estrogen receptor antagonist for use in a method of treatment of cancer | |
| AU2012201344A1 (en) | Vitamin K for prevention and treatment of skin rash secondary to anti-EGFR therapy | |
| HK1175691A (en) | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy | |
| HK1153125A (en) | Vitamin k analog for treatment of skin or mucosal ulceration | |
| Bruce et al. | 494 Mechanisms underlying MOR-DOR analgesic synergy in epidermal nerve fibers | |
| You et al. | 493 Determination of the critical sources of cAMP for Crisaborole activity in human keratinocytes | |
| Piccini et al. | 489 Sphingosine 1-phosphate receptors are expressed in human scalp hair follicles and their modulation by etrasimod warrants further investigation for management of alopecia areata | |
| Choi et al. | 490 A novel plant-derived compound induces apoptosis and cell death in mycosis fungoides | |
| Garman et al. | 491 Functional genomics screen identifies alternative targetable pathways for Merkel cell carcinoma | |
| Sivesind et al. | 492 Safety profile of topical cannabidiol and palmitoylethanolamide: A compilation of clinical and in vitro studies | |
| HK1111920B (en) | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy | |
| Pickering et al. | Oc028—A New Pharmaceutical Form Of Paracetamol: Efficacy Of Transmucous Buccal Paracetamol In Acute Pain Patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20081104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090413 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120306 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120604 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120611 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120629 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120706 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120906 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120906 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130402 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130802 |